Search

Your search keyword '"Quartier A"' showing total 371 results

Search Constraints

Start Over You searched for: Author "Quartier A" Remove constraint Author: "Quartier A" Topic business.industry Remove constraint Topic: business.industry
371 results on '"Quartier A"'

Search Results

1. Definition and Validation of the American College of Rheumatology 2021 Juvenile Arthritis Disease Activity Score Cutoffs for Disease Activity States in Juvenile Idiopathic Arthritis

2. Mevalonate Kinase Deficiency: A Cause of Severe Very-Early-Onset Inflammatory Bowel Disease

3. Représentation des professionnels face aux douleurs musculo-squelettiques chroniques idiopathiques de l’adolescent

4. Inflammatory bowel disease in children with systemic juvenile idiopathic arthritis

5. A young girl with severe polyarteritis nodosa successfully treated with tocilizumab: a case report

6. Absence of Association Between Abatacept Exposure and Initial Infection in Patients With Juvenile Idiopathic Arthritis

7. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open‐Label, Randomized Study

8. Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open‐Label, Active‐Treatment Extension Study

9. Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results

10. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee

11. Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis

12. Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)

13. Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept

14. Immunomodulatory treatment and surgical management of idiopathic uveitis and juvenile idiopathic arthritis-associated uveitis in children: a French survey practice

15. Genetic variation at ERBB3/IKZF4 and sexual dimorphism in epitope spreading in single autoantibody-positive relatives

16. Juvenile Idiopathic Arthritis-Associated Chronic Uveitis: Recent Therapeutic Approaches

17. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

18. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study

19. Differential Expression of Interferon-Alpha Protein Provides Clues to Tissue Specificity Across Type I Interferonopathies

20. From diagnosis to prognosis:Revisiting the meaning of muscle ISG15 overexpression in juvenile inflammatory myopathies

21. Sustained Remission After Haploidentical Bone Marrow Transplantation in a Child With Refractory Systemic Juvenile Idiopathic Arthritis

22. Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis

23. Laser Flare Photometry: A Useful Tool for Monitoring Patients with Juvenile Idiopathic Arthritis-associated Uveitis

24. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling

25. Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients

26. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children

27. Childhood- versus Adult-Onset Polyarteritis Nodosa Results from the French Vasculitis Study Group Registry

28. Avis d’experts pour le traitement des uvéites non infectieuses

29. The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)

30. Cryopyrinopathies

31. Comment on: Monogenic mimics of Behçet’s disease in the young

32. The multifaceted presentation of chronic recurrent multifocal osteomyelitis: A series of 486 cases from the Eurofever international registry

33. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

34. Efficacy of Continuous Interleukin 1 Blockade in Mevalonate Kinase Deficiency: A Multicenter Retrospective Study in 13 Adult Patients and Literature Review

35. Macrophage Activation Syndrome (MAS) in Systemic Juvenile Idiopathic Arthritis (sJIA): Treatment with Emapalumab, an Anti-Interferon Gamma (IFNγ) Monoclonal Antibody

36. Efficient response of an onshore Oscillating Water Column Wave Energy Converter using a one-phase SPH model coupled with a multiphysics library

37. 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria—methodological aspects

38. Real-World Experience and Impact of Canakinumab in Cryopyrin-Associated Periodic Syndrome: Results From a French Observational Study

39. OP0292 HIGH EFFICACY OF CANAKINUMAB IN SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA) ACROSS AGE GROUPS: COMPARISON OF CHILDREN, ADOLESCENTS AND YOUNG ADULTS BASED ON POOLED CLINICAL TRIAL RESULTS

40. Serious adverse events in children with juvenile idiopathic arthritis and other rheumatic diseases on tocilizumab - a real-world experience

41. Open Data for Differential Network Analysis in Glioma

42. Developments in AI and Machine Learning for Neuroimaging

43. Chronic idiopathic musculoskeletal pain in youth: a qualitative study

44. Anakinra in children and adults with Still's disease

45. Inhibition of IFNα secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology

46. Cutaneous Biodistribution: A High-Resolution Methodology to Assess Bioequivalence in Topical Skin Delivery

47. Circulating interferon‐α measured with a highly sensitive assay as a biomarker for juvenile inflammatory myositis activity: Comment on the Article by Mathian et al

48. THU0530 IDIOPATHIC RECURRENT PERICARDITIS: CLINICAL FINDINGS AND TREATMENT APPROACH

49. FRI0549 SARILUMAB, A HUMAN MONOCLONAL ANTIBODY TO THE INTERLEUKIN-6 (IL-6) RECEPTOR, IN POLYARTICULAR-COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): A 12-WEEK MULTINATIONAL OPEN-LABEL DOSE-FINDING STUDY

50. OP0055 EFFICACY OF CANAKINUMAB, ON A REDUCED DOSE OR A PROLONGED DOSE INTERVAL WITHOUT CONCOMITANT CORTICOSTEROIDS AND METHOTREXATE, IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS

Catalog

Books, media, physical & digital resources